Clinical characteristics of HSCT patients
| . | HSCT patients, N = 66 . | P . | ||
|---|---|---|---|---|
| No cGVHD, n = 16 . | Active cGVHD, n = 38 . | Resolved cGVHD, n = 12 . | No vs Active . | |
| Age, y | ||||
| Median | 56.6 | 61.7 | 63.1 | ns |
| Range | 25-74.9 | 25.9-75.6 | 32.6-69.5 | |
| Sex (%) | ||||
| M | 9 (56) | 23 (60) | 7 (58) | ns |
| F | 7 (44) | 15 (40) | 5 (42) | |
| Disease (%) | ||||
| Acute leukemia | 6 (38) | 15 (40) | 3 (25) | |
| HD, NHL, CLL, MM | 8 (50) | 15 (40) | 6 (50) | |
| MDS, MPN | 1 (6) | 7 (18) | 2 (17) | |
| Nonmalignant | 1 (6) | 1 (2) | 1 (8) | |
| Conditioning regimen (%) | ||||
| MAC | 4 (25) | 8 (21) | 6 (50) | ns |
| RIC | 12 (75) | 30 (79) | 6 (50) | |
| Donor type (%) | ||||
| MRD | 9 (56) | 10 (27) | 4 (33) | |
| MUD | 5 (31) | 24 (63) | 7 (58) | |
| mmUD | 2 (13) | 4 (10) | 1 (9) | |
| Graft source (%) | ||||
| PBSC | 13 (81) | 37 (97) | 9 (75) | |
| BM | 3 (19) | 1 (3) | 3 (25) | |
| GVHD prophylaxis (%) | ||||
| Tac-MTX | 6 (37) | 15 (40) | 6 (50) | |
| Tac-Sir | 3 (19) | 5 (13) | 1 (8) | |
| Tac-Sir-MTX | 7 (44) | 18 (47) | 5 (42) | |
| Months from HSCT to sample collection | ||||
| Median | 35.8 | 28.9 | 52.8 | .09 |
| Range | 12-87.9 | 9.6-123.8 | 11.7-140.9 | |
| Grade II-IV aGVHD (%) | ||||
| Yes | 0 | 17 (45) | 3 (25) | |
| . | HSCT patients, N = 66 . | P . | ||
|---|---|---|---|---|
| No cGVHD, n = 16 . | Active cGVHD, n = 38 . | Resolved cGVHD, n = 12 . | No vs Active . | |
| Age, y | ||||
| Median | 56.6 | 61.7 | 63.1 | ns |
| Range | 25-74.9 | 25.9-75.6 | 32.6-69.5 | |
| Sex (%) | ||||
| M | 9 (56) | 23 (60) | 7 (58) | ns |
| F | 7 (44) | 15 (40) | 5 (42) | |
| Disease (%) | ||||
| Acute leukemia | 6 (38) | 15 (40) | 3 (25) | |
| HD, NHL, CLL, MM | 8 (50) | 15 (40) | 6 (50) | |
| MDS, MPN | 1 (6) | 7 (18) | 2 (17) | |
| Nonmalignant | 1 (6) | 1 (2) | 1 (8) | |
| Conditioning regimen (%) | ||||
| MAC | 4 (25) | 8 (21) | 6 (50) | ns |
| RIC | 12 (75) | 30 (79) | 6 (50) | |
| Donor type (%) | ||||
| MRD | 9 (56) | 10 (27) | 4 (33) | |
| MUD | 5 (31) | 24 (63) | 7 (58) | |
| mmUD | 2 (13) | 4 (10) | 1 (9) | |
| Graft source (%) | ||||
| PBSC | 13 (81) | 37 (97) | 9 (75) | |
| BM | 3 (19) | 1 (3) | 3 (25) | |
| GVHD prophylaxis (%) | ||||
| Tac-MTX | 6 (37) | 15 (40) | 6 (50) | |
| Tac-Sir | 3 (19) | 5 (13) | 1 (8) | |
| Tac-Sir-MTX | 7 (44) | 18 (47) | 5 (42) | |
| Months from HSCT to sample collection | ||||
| Median | 35.8 | 28.9 | 52.8 | .09 |
| Range | 12-87.9 | 9.6-123.8 | 11.7-140.9 | |
| Grade II-IV aGVHD (%) | ||||
| Yes | 0 | 17 (45) | 3 (25) | |
aGVHD, acute GVHD; BM, bone marrow; CLL, chronic lymphocytic leukemia; F, female; HD, Hodgkin disease; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; mmUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; ns, not significant; PBSC, peripheral blood stem cell; RIC, reduced-intensity conditioning; Tac-MTX, tacrolimus-methotrexate; Tac-Sir, tacrolimus-sirolimus; Tac-Sir-MTX, tacrolimus-sirolimus-methotrexate.